BioSpace News Archive

Hub International Limited (HUB), a leading global insurance brokerage and Tennessee REALTORS®, one of the state’s largest trade associations, announced today the launch of one of the nation’s first association health plans (AHP) for a professional trade association under the new association rules.

Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced the appointment of Smital Shah to its board of directors as an independent director.

Valens GroWorks Corp. (CSE: VGW) (OTC: VGWCF) (the “Company” or “Valens”), a multi-licensed, provider of cannabis products and services focused on various proprietary extraction methodologies, distillation, cannabinoid isolation and purification, as well as associated quality testing, today reported financial results for its 2018 fiscal year ended November 30, 2018.

Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter ended December 31, 2018 on Monday, March 18, 2019, before the U.S. stock markets open.

Alliance for Regenerative Medicines’ Seventh Annual Investors Conference

Livoletide, a potential first-in-class treatment for Prader-Willi syndrome (PWS), will be featured in two poster sessions.

OrthoSpace was founded in 2009 and the Company’s InSpace product provides a highly differentiated technology for the treatment of massive irreparable rotator cuff tears.

Chugai Pharmaceutical Co., Ltd. announced that Roche received the decision from the European Commission confirming that Hemlibra® has EU marketing authorization for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors.

Targovax grants Zelluna an FTO license to Targovax patents and know-how to further enable development of Zelluna’s mutant RAS T-cell receptor therapies

Vifor pharma group reports strong 2018 results, exceeding raised guidance